AU2017325641B2 - Tyrosine kinase inhibitor and application thereof - Google Patents
Tyrosine kinase inhibitor and application thereof Download PDFInfo
- Publication number
- AU2017325641B2 AU2017325641B2 AU2017325641A AU2017325641A AU2017325641B2 AU 2017325641 B2 AU2017325641 B2 AU 2017325641B2 AU 2017325641 A AU2017325641 A AU 2017325641A AU 2017325641 A AU2017325641 A AU 2017325641A AU 2017325641 B2 AU2017325641 B2 AU 2017325641B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cancer
- mmol
- distillation
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610822529.0 | 2016-09-13 | ||
| CN201610822529.0A CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
| PCT/CN2017/089501 WO2018049861A1 (zh) | 2016-09-13 | 2017-06-22 | 酪氨酸激酶抑制剂及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017325641A1 AU2017325641A1 (en) | 2019-04-11 |
| AU2017325641B2 true AU2017325641B2 (en) | 2021-08-26 |
Family
ID=59982910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017325641A Active AU2017325641B2 (en) | 2016-09-13 | 2017-06-22 | Tyrosine kinase inhibitor and application thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10882853B2 (enExample) |
| EP (1) | EP3511327B1 (enExample) |
| JP (1) | JP7487921B2 (enExample) |
| KR (2) | KR102382039B1 (enExample) |
| CN (2) | CN107235896B (enExample) |
| AU (1) | AU2017325641B2 (enExample) |
| ES (1) | ES2902549T3 (enExample) |
| WO (1) | WO2018049861A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3070013A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| WO2019148043A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CR20250117A (es) | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| SG11202006921PA (en) * | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| CN112358469A (zh) * | 2020-03-18 | 2021-02-12 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| US8293897B2 (en) * | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
| AU2010229147B2 (en) * | 2009-03-21 | 2012-07-05 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN105884695B (zh) * | 2015-02-13 | 2019-02-26 | 山东轩竹医药科技有限公司 | 杂环衍生物类酪氨酸激酶抑制剂 |
| CN104817497B (zh) * | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN105017163A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| CN105001168A (zh) * | 2015-08-25 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 |
| CN105218445B (zh) * | 2015-08-25 | 2018-05-22 | 江苏中邦制药有限公司 | 一种酪氨酸激酶抑制剂Foretinib的制备方法 |
| CN105085416A (zh) * | 2015-08-25 | 2015-11-25 | 佛山市赛维斯医药科技有限公司 | 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
-
2016
- 2016-09-13 CN CN201610822529.0A patent/CN107235896B/zh active Active
- 2016-09-13 CN CN201910822704.XA patent/CN110437145A/zh active Pending
-
2017
- 2017-06-22 WO PCT/CN2017/089501 patent/WO2018049861A1/zh not_active Ceased
- 2017-06-22 KR KR1020217037589A patent/KR102382039B1/ko active Active
- 2017-06-22 ES ES17850066T patent/ES2902549T3/es active Active
- 2017-06-22 KR KR1020197010451A patent/KR20190045354A/ko not_active Ceased
- 2017-06-22 EP EP17850066.6A patent/EP3511327B1/en active Active
- 2017-06-22 JP JP2019515307A patent/JP7487921B2/ja active Active
- 2017-06-22 US US16/333,050 patent/US10882853B2/en active Active
- 2017-06-22 AU AU2017325641A patent/AU2017325641B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210143935A (ko) | 2021-11-29 |
| CN107235896B (zh) | 2019-11-05 |
| JP7487921B2 (ja) | 2024-05-21 |
| KR20190045354A (ko) | 2019-05-02 |
| EP3511327A1 (en) | 2019-07-17 |
| KR102382039B1 (ko) | 2022-04-01 |
| EP3511327B1 (en) | 2021-10-27 |
| US10882853B2 (en) | 2021-01-05 |
| WO2018049861A1 (zh) | 2018-03-22 |
| EP3511327A4 (en) | 2019-08-07 |
| CN110437145A (zh) | 2019-11-12 |
| ES2902549T3 (es) | 2022-03-28 |
| CN107235896A (zh) | 2017-10-10 |
| AU2017325641A1 (en) | 2019-04-11 |
| JP2019529435A (ja) | 2019-10-17 |
| US20190248772A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017325641B2 (en) | Tyrosine kinase inhibitor and application thereof | |
| CN106536503B (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
| JP6781150B2 (ja) | 癌の治療に有用な縮合二環式（ヘテロ）芳香族化合物 | |
| CN113527335A (zh) | 作为egfr抑制剂的大环类化合物及其应用 | |
| WO2017079140A1 (en) | Inhibitors of ret | |
| CN107735399A (zh) | 作为蛋白质激酶的调节剂的手性二芳基大环 | |
| EP3697786B1 (en) | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | |
| JP2021512055A (ja) | Ｔａｍファミリーキナーゼ／及びｃｓｆ１ｒキナーゼ阻害剤及びその用途 | |
| TWI615392B (zh) | 新型稠合吡啶衍生物的馬來酸鹽晶型及其用途 | |
| JP2021536436A (ja) | キノリン誘導体から調製される新規な阻害剤 | |
| WO2018191587A1 (en) | Tam kinase inhibitors | |
| HK1248226A1 (en) | 1,4-disubstituted imidazole derivatives | |
| EP2928466A1 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
| US20230303569A1 (en) | Heterocyclic compounds as therapeutic agents | |
| EP4293029B1 (en) | Azaheteroaryl compound, preparation method therefor, and application thereof | |
| CN112625026B (zh) | Tam家族激酶抑制剂的喹啉衍生物 | |
| WO2015144911A1 (en) | 3-phenyl-7-hydroxy-isocoumarins as macrophage migration inhibitory factor (mif) inhibitors | |
| EP3036234A1 (en) | Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders | |
| CN110407839A (zh) | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 | |
| WO2024012570A1 (zh) | 一种含氮杂环衍生物及其组合物和药学上的应用 | |
| WO2019029554A1 (zh) | 磺酰胺类衍生物、其制备方法及其在医药上的用途 | |
| WO2024255845A1 (zh) | 一类蛋白降解剂及其药物组合物和用途 | |
| WO2025162427A1 (en) | Indazole compound and pharmaceutical composition, preparation method and use thereof | |
| HK40104987A (en) | Azaheteroaryl compound, preparation method therefor, and application thereof | |
| TW202448441A (zh) | 脯氨醯羥化酶抑制劑及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: LANOVA MEDICINES LIMITED Free format text: FORMER APPLICANT(S): SHANGHAI XIANGJIN BIOTECHNOLOGY CO., LTD |
|
| FGA | Letters patent sealed or granted (standard patent) |